Basic information
Biomarker: FOLR1
Histology type: endometrial carcinoma
Cohort characteristics
Country: USA
Region: DC
Followed up time :
Subgroup 1 name : overexpression
Subgroup 1 number: 50
Subgroup 2 name: Low expression
Subgroup 2 number: 242
Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
---|---|---|---|---|---|---|---|---|
485 | endometrial adenocarcinoma | 485 |
Sample information
Conclusion: Our data show that FOLR1 overexpression is not only a biomarker associated with endometrial cancer, but it also appears to be a prognostic factor associated with adverse outcome. These findings suggest that FOLR1 may be an appealing target for biological therapies in some types of endometrial carcinomas.
Sample type : tissue
Sample method: tissue microarray
Expression pattern : overexpression(staining= 2–3)
Expression elevation: FOLR1 staining was graded using the following criteria: 0 = no staining; 1 =weak cytoplasmic staining, no membranous immunoreactivity; 2 =moderate cytoplasmic staining with weaker membranous immunoreactivity; 3 = strong cytoplasmic and membranous immunoreactivity. The results were recorded as positive (consistent with overexpression) if at least 10% of the neoplastic cells exhibited a staining grade of 2–3. A case was considered as negative on TMA only if all four cores, representative of the case had 0–1 staining. The overall intensity of staining of the case was recorded for the core with the strongest intensity when there was variation between cores for a given case
Disease information
Statictics: Mean (SD)
Subgroup 1 age: 65.6 (12.0)
Subgroup 2 age: 61.9 (13.5)
Related information
Funtion Uniprot: Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate and folate analogs into the interior of cells (PubMed:23851396, PubMed:23934049, PubMed:2527252, PubMed:8033114, PubMed:8567728, PubMed:19074442). Has high affinity for folate and folic acid analogs at neutral pH (PubMed:23851396, PubMed:23934049, PubMed:2527252, PubMed:8033114, PubMed:8567728). Exposure to slightly acidic pH after receptor endocytosis triggers a conformation change that strongly reduces its affinity for folates and mediates their release (PubMed:8567728). Required for normal embryonic development and normal cell proliferation (By similarity).
UniProt ID: P15328
UniProt Link: https://www.uniprot.org/uniprotkb/P15328/entry
Biological function from UniProt: #Transport
Molecular function from UniProt:
Tissue specificity from UniProt: Primarily expressed in tissues of epithelial origin. Expression is increased in malignant tissues. Expressed in kidney, lung and cerebellum. Detected in placenta and thymus epithelium.
Subcellular UniProt: #Cell membrane #Cytoplasmic vesicle #Endosome #Membrane #Secreted
Alternative name from UniProt:
Recommended name: Folate receptor alpha
Gene name from HGNC: FOLR1 (FOLR, FRα)
HPA class: Disease related genes Human disease related genes Metabolic proteins Potential drug targets Transporters
AlphaFold DB: P15328
AlphaFold Link: https://alphafold.ebi.ac.uk/entry/P15328
HPA link: https://www.proteinatlas.org/ENSG00000110195-FOLR1
Tissue specificity RNA from HPA: Tissue enhanced (choroid plexus, fallopian tube, lung, salivary gland)
Single cell type specificity Cell type enhanced (Alveolar cells type 1, Cytotrophoblasts, Proximal tubular cells, Collecting duct cells, Club cells, Syncytiotrophoblasts, Alveolar cells type 2, Breast glandular cells)
Immune cell specificity: Not detected in immune cells
Subcellular summary HPA Located in Nuclear membrane (Single cell variability)
Cancer prognostic summary HPA Prognostic marker in liver cancer (unfavorable)
Pathology link: https://www.proteinatlas.org/ENSG00000110195-FOLR1/pathology
Pathology endo: https://www.proteinatlas.org/ENSG00000110195-FOLR1/pathology/endometrial+cancer
Phenotype ID: 613068
Disease: Neurodegeneration due to cerebral folate transport deficiency (NCFTD)
Note1: The disease is caused by variants affecting the gene represented in this entry;Overexpressed in several cancer types and promotes malignancy;
OMIM: 136430
OMIM link1: https://www.omim.org/entry/613068
OMIM link2: https://www.omim.org/entry/136430;https://www.omim.org/entry/613068;
HGNC ID: HGNC:3791
HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3791